In the News

part d statement
January 15, 2021
AAM and its Biosimilars Council applaud the decision by CMS to update the Part D program and allow plans with lower cost-sharing.
biosimilars news april 2020
December 10, 2020
AAM and its Biosimilars Council look forward to working with President-elect Biden’s U.S. Trade Representative (USTR)-designee Katherine Tai.
xavier becerra
December 7, 2020
AAM and its members look forward to working with Xavier Becerra to secure patient access to safe, effective and affordable medicines.
Approved Biosimilars
November 11, 2020
The Association for Accessible Medicines looks forward to working with the incoming Biden-Harris administration to achieve our shared goal of increasing access to safe, effective and affordable generic and biosimilar prescription medicines for all Americans.
IQVIA Biosimilars in the US
October 6, 2020
Today’s IQVIA report confirms that biosimilars are gaining ground to the benefit of patients and the U.S. health care system, but also raises a red flag about the long-term sustainability of the biosimilar market.
August 6, 2020
Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain and are working with policymakers to add to our significant manufacturing presence in the United States

Recent Tweets

At the #GRxBiosims conference in November 2020, HHS Secretary @SecAzar spoke about the transformation #biosimilars could bring to patient care. Biosimilars have the potential to bring billions in savings to America’s patients.

Watch sessions on demand:

Load More...